

RECENT ADVANCES AGAINST BLOOD CANCERS

In the 12 months spanning August 1, 2017 to July 31, 2018, the FDA approved new treatment options for certain patients with the following seven types of blood cancer, or hematologic cancer:

Acute Lymphoblastic Leukemia (ALL) in adults

- Inotuzumab ozogamicin (Besponsa) is a molecularly targeted therapeutic approved in August 2017.

ALL in Children and Young Adults

- Tisagenlecleucel (Kymriah) is an immunotherapeutic and gene therapy approved in August 2017.

Acute Myeloid Leukemia (AML)

- Enasidenib (Idhifa) is a molecularly targeted therapeutic approved in August 2017.
- Vyxeos is a fixed combination of the cytotoxic chemotherapeutics daunorubicin and cytarabine formulated together in a single nanoformulation approved in August 2017.
- Gemtuzumab ozogamicin (Mylotarg) is a molecularly targeted therapeutic approved in September 2017.
- Ivosidenib (Tibsovo) is a molecularly targeted therapeutic approved in July 2018.

Cutaneous T-cell lymphoma

- Brentuximab vedotin (Adcetris) is a molecularly targeted therapeutic approved in November 2017.

Erdheim-Chester Disease

- Vemurafenib (Zelboraf) is a molecularly targeted therapeutic approved in November 2017.

Follicular Lymphoma

- Copanlisib (Aliqopa) is a molecularly targeted therapeutic approved in September 2017.

Large B Cell Lymphoma

- Axicabtagene ciloleucel (Yescarta) is an immunotherapeutic and gene therapy approved in October 2017.
- Tisagenlecleucel is an immunotherapeutic and gene therapy approved in May 2018.
- Pembrolizumab (Keytruda) is an immunotherapeutic approved in June 2018.

Mantle Cell Lymphoma

- Acalabrutinib (Calquence) is a molecularly targeted therapeutic approved in October 2017.

